Branded

MALVERN, Pa. — The U.S. subsidiary of British drug maker GlaxoSmithKline and U.S.-based Auxilium Pharmaceuticals will co-promote a testosterone-replacement drug, the two said Monday.

GSK and Auxilium announced an agreement for the co-promotion of Testim 1% (testosterone gel), used in men with conditions related to deficiency or absence of the hormone.

NEW YORK — Federal and industry officials have been negotiating a federal track-and-trace system as part of a reauthorization of the Prescription Drug User Fee Act, according to published reports.

PARSIPPANY, N.J. — Generic drug maker Watson Pharmaceuticals is challenging the patent protection of a contraceptive drug made by Warner Chilcott, Watson said Friday.

The company announced that it had filed a regulatory application with the Food and Drug Administration for norethindrone acetate and ethinyl estradiol tablets in the 1-mg/0.01-mg strength and ethinyl estradiol and ferrous fumarate tablets in the 0.01-mg/75-mg strength. The treatment is a generic version of Warner Chilcott's Lo Loestrin Fe.

ATLANTA — People with higher levels of education and higher income have lower rates of many chronic diseases compared with those with less education and lower income levels, according to "Health, United States, 2011" — the government’s annual comprehensive report on Americans’ health released Wednesday.

AMBLER, Pa. — Wolters Kluwer Health has introduced what it called the first mobile application for the Nursing Drug Handbook, the company said Thursday.

Published by Lippincott Williams & Wilkins, the app is available for Apple and Android devices and is a mobile version of the popular reference for nurses that includes weekly updates.

NEW YORK — More than 80% of health plans would require a drug manufacturer to demonstrate a clear clinical benefit compared with current branded and generic treatments in order for its drug to be placed in the plan's formulary, according to a new survey.

NEW YORK — An experimental kidney cancer drug made by Pfizer didn't extend the time in which patients survived without their disease worsening when compared with a competing drug, according to results of a late-stage clinical trial released Wednesday.

Medication nonadherence costs the U.S. healthcare system about $290 billion per year, according to New England Healthcare Institute. That big and scary number — the kind whose sheer enormity can make one’s eyes glaze over — is now even bigger.